Allogeneic CD19-CAR-T Cell Infusion After Allogeneic Hematopoietic Stem Cell Transplantation in B Cell Malignancies

Overview

Journal J Hematol Oncol

Publisher Biomed Central

Specialties Hematology
Oncology

Date 2017 Feb 2

PMID 28143567

Citations 64

Authors

Jun Liu

Jiang F Zhong

Xi Zhang

Cheng Zhang

Affiliations

Soon will be listed here.

Abstract

Background: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is considered the cornerstone in treatment of hematological malignancies. However, relapse of the hematological disease after allo-HSCT remains a challenge and is associated with poor long-term survival. Chimeric antigen receptor redirected T cells (CAR-T cells) can lead to disease remission in patients with relapsed/refractory hematological malignancies. However, the therapeutic window for infusion of CAR-T cells post allo-HSCT and its efficacy are debatable.

Main Body: In this review, we first discuss the use of CAR-T cells for relapsed cases after allo-HSCT. We then review the toxicities and the occurrence of graft-versus-host disease in relapsed patients who received CAR-T cells post allo-HSCT. Finally, we review clinical trial registrations and the therapeutic time window for infusion of CAR-T cells post allo-HSCT.

Conclusions: The treatment of allogeneic CAR-T cells is beneficial for patients with relapsed B cell malignancies after allo-HSCT with low toxicities and complications. However, multicenter clinical trials with larger sample sizes should be performed to select the optimal therapeutic window and confirm its efficacy.

Citing Articles

A Retrospective Study on the Role of Tranexamic Acid in Reverse Total Shoulder Arthroplasty for Trauma Patients With Complex Proximal Humerus Fractures.

Rana T, Mushtaq H, Memon K, Chan S, Kalogrianitis S Cureus. 2025; 17(1):e78083.

PMID: 40013204 PMC: 11864774. DOI: 10.7759/cureus.78083.

Utilization of donor CLL-1 CAR-T cells for the treatment of relapsed of acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation.

Zhang M, Zhang X, Wang J, Lu W, Xiao X, Lyu H Front Immunol. 2025; 15:1491341.

PMID: 39896798 PMC: 11782272. DOI: 10.3389/fimmu.2024.1491341.

GVHD after CAR T-cell therapy post allogeneic hematopoietic cell transplantation - successfully treated by extracorporeal photopheresis.

Farid K, Bug G, Schmitt A, Lang F, Schubert M, Haberkorn U Front Immunol. 2024; 15:1500177.

PMID: 39624098 PMC: 11609171. DOI: 10.3389/fimmu.2024.1500177.

Generating advanced CAR-based therapy for hematological malignancies in clinical practice: targets to cell sources to combinational strategies.

Zhou S, Yang Y, Jing Y, Zhu X Front Immunol. 2024; 15:1435635.

PMID: 39372412 PMC: 11449748. DOI: 10.3389/fimmu.2024.1435635.

Syngeneic Mouse Models for Pre-Clinical Evaluation of CAR T Cells.

Ahmed E, Cutmore L, Marshall J Cancers (Basel). 2024; 16(18).

PMID: 39335157 PMC: 11430534. DOI: 10.3390/cancers16183186.

References

Morsut L, Roybal K, Xiong X, Gordley R, Coyle S, Thomson M . Engineering Customized Cell Sensing and Response Behaviors Using Synthetic Notch Receptors. Cell. 2016; 164(4):780-91. PMC: 4752866. DOI: 10.1016/j.cell.2016.01.012. View

Nagafuji K, Miyamoto T, Eto T, Kamimura T, Taniguchi S, Okamura T . Monitoring of minimal residual disease (MRD) is useful to predict prognosis of adult patients with Ph-negative ALL: results of a prospective study (ALL MRD2002 Study). J Hematol Oncol. 2013; 6:14. PMC: 3574830. DOI: 10.1186/1756-8722-6-14. View

Zuo Y, Wang J, Lu A, Jia Y, Wu J, Dong L . [Chimeric antigen receptors T cells in treatment of a relapsed pediatric acute lymphoblastic leukemia, relapse after allogenetic hematopoietic stem cell transplantation: case report and review of literature review]. Zhonghua Xue Ye Xue Za Zhi. 2016; 37(2):115-8. PMC: 7348202. DOI: 10.3760/cma.j.issn.0253-2727.2016.02.006. View

Rambaldi A, Biagi E, Bonini C, Biondi A, Introna M . Cell-based strategies to manage leukemia relapse: efficacy and feasibility of immunotherapy approaches. Leukemia. 2014; 29(1):1-10. DOI: 10.1038/leu.2014.189. View

Marcus A, Eshhar Z . Allogeneic chimeric antigen receptor-modified cells for adoptive cell therapy of cancer. Expert Opin Biol Ther. 2014; 14(7):947-54. DOI: 10.1517/14712598.2014.900540. View

Benjamin J, Stein A . The role of blinatumomab in patients with relapsed/refractory acute lymphoblastic leukemia. Ther Adv Hematol. 2016; 7(3):142-56. PMC: 4872177. DOI: 10.1177/2040620716640422. View

Maude S, Frey N, Shaw P, Aplenc R, Barrett D, Bunin N . Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014; 371(16):1507-17. PMC: 4267531. DOI: 10.1056/NEJMoa1407222. View

Khan M, Gul Z . Blinatumomab may induce graft versus host leukemia in patients with pre-B ALL relapsing after hematopoietic stem cell transplant. Clin Case Rep. 2016; 4(8):743-6. PMC: 4974418. DOI: 10.1002/ccr3.604. View

Roddie C, Peggs K . Donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation. Expert Opin Biol Ther. 2011; 11(4):473-87. DOI: 10.1517/14712598.2011.554811. View

10.

Yan C, Wang Y, Wang J, Chen Y, Chen Y, Wang F . Minimal residual disease- and graft-vs.-host disease-guided multiple consolidation chemotherapy and donor lymphocyte infusion prevent second acute leukemia relapse after allotransplant. J Hematol Oncol. 2016; 9(1):87. PMC: 5024494. DOI: 10.1186/s13045-016-0319-5. View

11.

Davila M, Riviere I, Wang X, Bartido S, Park J, Curran K . Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014; 6(224):224ra25. PMC: 4684949. DOI: 10.1126/scitranslmed.3008226. View

12.

Brudno J, Somerville R, Shi V, Rose J, Halverson D, Fowler D . Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease. J Clin Oncol. 2016; 34(10):1112-21. PMC: 4872017. DOI: 10.1200/JCO.2015.64.5929. View

13.

Wu J, Fu J, Zhang M, Liu D . Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia. J Hematol Oncol. 2015; 8:104. PMC: 4558758. DOI: 10.1186/s13045-015-0195-4. View

14.

Cai B, Guo M, Wang Y, Zhang Y, Yang J, Guo Y . Co-infusion of haplo-identical CD19-chimeric antigen receptor T cells and stem cells achieved full donor engraftment in refractory acute lymphoblastic leukemia. J Hematol Oncol. 2016; 9(1):131. PMC: 5124292. DOI: 10.1186/s13045-016-0357-z. View

15.

Brentjens R, Davila M, Riviere I, Park J, Wang X, Cowell L . CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013; 5(177):177ra38. PMC: 3742551. DOI: 10.1126/scitranslmed.3005930. View

16.

Bhojwani D, Pui C . Relapsed childhood acute lymphoblastic leukaemia. Lancet Oncol. 2013; 14(6):e205-17. DOI: 10.1016/S1470-2045(12)70580-6. View

17.

Grupp S, Kalos M, Barrett D, Aplenc R, Porter D, Rheingold S . Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013; 368(16):1509-1518. PMC: 4058440. DOI: 10.1056/NEJMoa1215134. View

18.

Magnani C, Biondi A, Biagi E . Donor-derived CD19-targeted T cells in allogeneic transplants. Curr Opin Hematol. 2015; 22(6):497-502. DOI: 10.1097/MOH.0000000000000178. View

19.

Castagna L, Sarina B, Bramanti S, Perseghin P, Mariotti J, Morabito L . Donor lymphocyte infusion after allogeneic stem cell transplantation. Transfus Apher Sci. 2016; 54(3):345-55. DOI: 10.1016/j.transci.2016.05.011. View

20.

Porter D, Levine B, Kalos M, Bagg A, June C . Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011; 365(8):725-33. PMC: 3387277. DOI: 10.1056/NEJMoa1103849. View